Huaiqihuang granule
Phase 3Small molecule
Huaiqihuang granule is one of 67 small molecule programs targeting Nephrotic Syndrome. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Immune Thrombocytopenia
#DrugCompanyPhaseTrials
1Promacta
GSKApproved
Rituxan
RocheApproved
Decadron
AAspen Global Incorporated
Approved
Plaquenil
Jazz PharmaceuticalsApproved
Oncovin
Eli LillyApproved
Rayos
RRoxane Laboratories
Approved
Imuran
LLegacy Health System
Approved
Doptelet
AAkarx
Phase 3
Vyvgart
ArgenxPhase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Huaiqihuang granule. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details